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The introduction of recombinant human erythropoietin (RHUEPO) has revolutionised the treatment 
strategies for patients suffering with anaemia of chronic renal disease and chronic heart failure. Clinical 
studies and several observational evidences have demonstrated that RHUEPO is also useful in various 
non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection 
and preoperative therapies. The successful treatment of all the anaemic related malfunctions with 
recombinant human erythropoietin (RHUEPO) has become a standard treatment tool for dialysis pat-
ients and as an interesting therapeutic option for several forms of non-renal anaemia. As a cones-
quence of both, RHUEPO has achieved the highest annual sales worldwide and the potential of it 
increases its scope in the future prospective also. 
 






Erythropoietin is a glycoprotein which stimulates the red 
blood cells in the bone marrow. In 1985, the human 
erythropoietin gene was cloned (Tabbara et al., 1993). 
The introduction of Recombinant Human Erythropoietin 
(RHUEPO) has revolutionized the therapeutic approa-
ches in treating the patients with anaemia of chronic renal 
disease. Clinical studies have demonstrated that recom-
binant human erythropoietin is also useful in various-
uraemic conditions including hematological and oncolo-
gical disorders, prematurity, HIV infection and other 
therapies (Ng et al., 2003).  Several studies showed that 
anaemia observed in patients with chronic heart failure 
(CHF) is associated with worsened symptoms and 
survival, a significant improvement is seen when treated 
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Glaspy et al., 2001, Locatelli et al., 2001) 
Despite impressive advances in safety of blood supply 
(Levin et al., 1999), the search for therapeutic alterna-
tives to blood continues (Floey et al., 1996; Parfrey et al., 
1996).  Several studies in dialysis patients, including an 
analysis of the US Medicare database (Ma et al., 1999) 
demonstrated an inverse relationship between haemato-
crit and patient survival. Prospective Cohort studies 
identified anaemia as an independent risk factor for 
growth in the dialysis and pre-dialysis population (Kai-
uwe Eckardt, 2001).  An uncontrolled pilot study and a 
small controlled trial by the same investigators have 
suggested recently that in patient with severe heart 
failure, an increase in haemoglobin levels following com-
bined therapy with recombinant human erythropoietin and 
iron leads to an impressive improvement of symptoms 
and retards disease progression (Silverberg et al., 2003). 
Knowledge of scientific and physiologic bases for the 
pharmacological use of erythropoietin has led to clinical  




trials in patients undergoing elective surgery especially in 
the United States (Krantz, 1991; Adamson et al., 1994). 
This review reveals the possible applications of 
erythropoietin, its potential and an over-view on 
overcoming some of the anaemic related malfunctions in 
humans with RHUEPO.   
 
 
LOCATION AND SPECIFICATION OF ERYTHRO-
POIETIN 
 
Erythropoietin is a glycoprotein with a molecular weight of 
30.4 kD. The human erythropoietin gene is situated at 
chromosome 7q11-22, consisting of five exons and four 
introns, which produce a post transcriptional single poly-
peptide containing 193 aminoacids (Jelkmann, 1992).  
During the post-translational modification, glycosylation 
occurs with the addition of three N-linked (at Asn-24, 
Asn-38 and Asn-83) and O-linked (at Ser-126) acidic 
oligosaccharides, the formation of two disulphide bonds 
at Cys-7 to Cys-161 and at Cys-29 to Cys-33, concomi-
tant with the removal of the 27 aminoacid hydrophobic 
secretory sequence (Law et al., 1986). Circular dichorism 
spectral analysis has proposed that its secondary struc-
ture contains 50% of helix moiety, with spatial arrange-
ment of two helical pairs running antiparallel similar to 
that of growth hormone (Inoue et al., 1995). The N-
glycosylated moiety of recombinant human erythropoietin 
has three main functional units; the main core, the 
branched portion and the terminal component with each 
unit having a specific role. The function of the O-glycosy-
lated unit, a component constituting about 3% of the total 
mass of recombinant human erythropoietin, remains to 
be defined (Ng’ et al., 2003). 
 
 
ROLE OF ERYTHROPOIETIN IN HUMANS  
 
The Erythropoietin (EPO), a glycoprotein hormone produ-
ced primarily by cells of the peritubular capillary endothe-
lium of the kidney, is responsible for the regulation of red 
blood cell production. Secondary amounts of the horm-
one are synthesized in liver hepatocytes of healthy 
adults. In premature as well as full term infants, liver is 
the primary site of EPO production (Hawazin Faruki et al., 
1995). The Erythropoietin has the ability to reduce the 
diseases related with heart, kidney, lungs, bone marrow, 
brain and other exercise parameters such as muscle 
oxidative metabolism and fore arm vasodilation. 
Anaemia is commonly observed in patients with chronic 
heart failure (CHF) and is related to the severity of dise-
ase (Wiek Van Gilst et al., 2003).  Evidence for a relation 
between anaemia and cardiac morbidity and mortality 
was provided by retrospectively examined studies (Al – 
Ahmad et al., 2003). The role of recombinant human 
erythropoietin therapy in CHF patients showed many 
beneficial effects (Silverberg et al., 2001). Clinical studies 
have shown that recombinant human erythropoietin ther-





blood transfusions and improves quality of life (Eschbach, 
1994). Furthermore, it optimizes patient’s haemodynamic 
status thus minimizing the risk of progression of left 
ventricular hypertrophy and its associated mortality; it 
leads to the improvement of physical performance and 
cognitive function (Mocks, 2000; Silverberg et al., 2001). 
Some clinical conditions give rise to tissue hypoxia 
including anaemia, lung disease, or cyanotic heart 
disease which further leads to the increase in the levels 
of serum erythropoietin (Hawazin Faruki et al., 1995.) 
Certain bone marrow disorders, such as myelody-splastic 
syndrome and aplastic anaemia, may also be associated 
with high serum levels of erythropoietin. A primary 
elevation of erythropoietin levels can also occur in certain 
tumors, resulting in erythropoiesis (Tabbara, 1993) and 
recombinant human erythropoietin is also used in the 
treatment of tumors. The multifunctional role of 
erythropoietin has further been confirmed by the disco-
very of a specific erythropoietin receptor (EPOR) system 
in the central nervous system (Buemi et al., 2000). The 
hypothesis suggested that the brain of a patient with 
depression may be in state of hypoxia, which may induce 
erythropoietin production (Nakamura et al., 2000).  Rece-
ntly it was discovered that erythropoietin also protects 
neurons. Recombinant human erythropoietin is given 
after chemotherapy and used in the treatment of solid 
tumors. (Case et al., 1993; Casinu et al., 1994). RHUE-
PO prevents chemotherapy-induced anaemia in children 
(Csaki et al., 2005). EPO was also applied as performa-
nce enhancing drug in athletes (Adamson et al., 1991; 
Ekblom et al., 1991). Therefore the RHUEPO has signifi-
cant implications concerning its use in clinical practice.  




Deficiency of EPO leads to diverse abnormalities 
 
The lack of erythropoietin in humans leads to several 
anaemic related malfunctions as well as other disorder. 
Anaemia is frequently observed in patients with chronic 
renal faiilure (CRF).  Renal anaemia is an important risk 
factor for the development of cardiovascular disease 
(Levin et al., 1999). Besarab et al. (1998) studied haemo-
dialysis patients with clinically evident ischaemic heart 
disease (or) CHF (Fellner et al., 1993; Metivier et al., 
2000).  Patients with higher haemoglobin levels showed a 
significantly reduced left ventricular end-diastolic diame-
ter haemodynamic status (Mocks, 2000). It also increa-
ses hypertension and results in some adverse events 
(Cody et al., 2001). The decreased dosage of RHUEPO 
provides an additive and rapid effect in the correction of 
renal anaemia during the pre-dialysis period (Eknoyan, 
2001). The reduction in EPO causes delayed graft func-
tion (or) graft thrombosis and also reduces sensitisation 
as a result of random blood transfusion (Muirhead, 1999).  
A recent study in Sweden has shown that pre-transplant 





– operative blood transfusion with no evidence of 
worsening the transplant outcome (Linde et al., 2001). 
There exists an evidence for a relation between 
anaemia and cardiac morbidity and mortality (Horwich et 
al., 2002). The random studies revealed that CHF is 
diagnosed in many people and became the risk of death 
(Clellan et al., 2002).  Mild anaemia in diabetics and non-
diabetics resulted in an improved cardiac function 
(Silverberg et al., 2003). Heart failure is one of the results 
due to the decrease in the haemoglobin levels (Besarab 
et al., 1998).  The severity of anaemia increases with the 
worsening of congestive cardiac failure (Silverberg et al., 
2002). The potential mechanisms by which anaemia 
would worsen CHF include exacerbation of myocardial 
and peripheral hypoxia, increased venous return and 
cardiac work and consequent left ventricular hypertrophy 
(Al-Ahmad et al., 2001). Hypoxia could also potentially 
lead to activation of neurohormones and cytokines.  In 
turn, cytokines can exacerbate the anaemia, leading to a 
vicious cycle, the recently coined cardiorenal anaemia 
syndrome (Means et al., 1999). The increased production 
of EPO in CHF patients with anaemia may reflect the 
presence of renal hypoxia and a compensatory attempt to 
augment O2 delivery to peripheral tissues through 
erythrocytosis (Volpe et al., 1994; Kumagai et al., 1999).  
Large doses of EPO results increase in blood pressure 
(Silverberg et al., 2001), and there is no effect on resting 
or exercise blood pressure (Maschio, 1995; Fishbane et 
al., 1995). 
Apoptosis has been implicated as a mechanism that 
contributes to the loss of cardiomyocytes in CHF and 
ischaemic injury. (Olivetti et al., 1997; Siren et al., 2001). 
The implication of recombinant human erythropoietin also 
has beneficial effects on these anaemic diseases as well.  
(Saraste et al., 1997). Many experiments with mice which 
included the knocking out of the gene expressing EPO 
resulted in ventricular hypoplasia (Vander Meer et al., 
2003). The defect in the expression of EPO gene results 
in the effect of EPO on angiogenesis (Ashley et al., 
2002). Recent studies have been conducted to evaluate 
the possible effect in cardiac ischaemia and myocardial 
infection assessed by the role of EPO in vitro and in vivo 
with adult rat models (Calvillo et al., 2003). 
Low level expression of EPO and its receptors has 
since long been reported in the brain (Tan et al., 1991; 
Marti et al., 1996).  High doses of RHUEPO was found to 
be neuro protective in different models of brain injury, 
even when the application was started several hours after 
the injury (Brines et al., 2000). In general, administration 
of EPO protects retinal neurons from acute ischemia-
reperfusion injury (Junk et al., 2005).  EPO may in 
addition, become an emergency medication, in patients 
with stroke or traumatic brain injury. 
Other than the several anaemias (Table 1), there exists 
some other disorders such as haemolysis i.e., the fall of 
haemoglobin as a result of RBC disorders like hereditary 
spherocytosis and haemoglobinopathies  (Tchernia et al.,  




2000; Shapira et al., 2001) and neuroprotection i.e., the 
use of RHUEPO has been shown to limit the degree of 
ischaemic cerebral damage and spinalcord injury, toget-
her with expending neurological recovery (Cerami, 2001; 
Gorio et al., 2002).  
Lack of EPO also results in the decrease in the func-
tioning of skeletal muscle and O2 use as well as endothe-
lial function (Mohan et al., 1999). The decreasing levels 
of EPO have a drastic effect on the exercise capacity, 
especially in athletes (Ma et al., 1999). 
 
 
Clinical treatments for malfunctions  
 
There are several clinical treatments other than the 
introduction of recombinant human erythropoietin thera-
py. These clinical therapies are designed as medical ther-
apies, surgical therapies and downshifting of risk for new 
surgical therapy. The medical therapies include the admi-
nistration of nitrated, mercurial diuretics and other chemi-
cals from early part of the twentieth century.  The usage 
of thiazide diuretics was on the way even before twen-
tieth century (Calduch et al., 1995; Cattaneo et al., 1996). 
Other chemicals such as nitropruside and hydratazine 
isosorbide dinitrate combination came into existence as 
medical therapies. The surgical therapies were done 
mainly for the treatment of chronic heart failure and seve-
re heart attacks.  The artery bypass surgery clarified its 
role in overcoming the coronary heart disease (Digicaylio-
glu et al., 1995; Dobbing et al., 1999).  
The downshifting of risk for new surgical therapy recog-
nizes the success or new surgical process followed in 
some cases by a cycle of improving definition for these 
evolutionized therapies (Eckardt et al., 1990). The recom-
mended specific medication of iron, vitamin – B12 and 
folic acid promotes erythropoiesis (Lawrence Goodnough 
et al., 1997). Rather than all these therapies, the 
recombinant human erythropoietin therapy is the forward 




CLONING AND PRODUCTION OF RECOMBINANT 
HUMAN ERYTHROPOIETIN 
  
 The production of recombinant human erythropoietin 
began with a search for the gene coding for erythropoi-
etin (EPO). Two radiolabeled pools of oligonucleotide 
probes were designed based on amino acid sequence 
information obtained from human urinary EPO. Each 
probe, consisting of complex mixtures of 128 short syn-
thetic sequences of DNA, was used to search a human 
genomic library for clones containing the human EPO 
gene sequence. To verify that the isolated clones contai-
ned the complete functional gene encoding human EPO, 
these sequences were expressed in Chinese hamster 
ovary cells, and the secreted recombinant human ery-
thropoietin was purified, characterized, and compared 
with the human urinary hormone using a variety of differ- 




Table 1. Anaemias resulting from lack of erythropoietin. 
 
Disorder Author 
Anaemia associated with bone marrow and stem cell transplantation Klaesson, 1999 
Anaemia of prematurity Reiter et al., 2000; Ledbetter et al, 2000 
Anaemia associated with HIV infection Volberding, 2000 
Anaemia associated with malignancy Van Bommel et al., 2001; Fernandes Jr. et al., 2001 




ent techniques. Results of these studies indicate that 
recombinant human erythropoietin is virtually indistinguis-
hable from human urinary EPO in its biochemical and 
immunological properties. It is a 165-amino acid protein 
whose primary sequence is identical to that of urine-
derived EPO (Inoue et al., 1995). The gene coding for 
human erythropoietin was obtained from human genomic 
DNA. The gene used does not include sequences from 
regions at 1 (5’ of first translated ATG and 2) 3’ of the 
stop codon of the erythropoietin gene. The gene was 
cloned into an expression plasmid for eukaryotic cells 
that have a sole expression control elements, the early 
promoter of SV40 virus and its polyadenylation signal. 
Recombinant cells resulting from transfection with genetic 
constructs provided an unexpectedly high level of protein 
expression of 50 mg of recombinant human erythropoi-
etin per litre of culture medium per day (Kurnet et al., 
2003). The subsequent development of large-scale cell 
culture and production techniques has made available 
sufficient amounts of recombinant human erythropoietin 
for clinical use in the treatment of the debilitating anemia 
that almost invariably accompanies chronic renal failure 
(Egrie, 1990). The erythropoietin gene, when introduced 
into chinese hamster ovary cells produces erythropoietin 




Stimulation of erythropoiesis by in vivo gene therapy  
 
Erythropoietin is the principal regulator of erythropoiesis. 
To evaluate the concept that in vivo gene transfer might 
be used as an alternative to recombinant human EPO in 
applications requiring a 1- to 3-week stimulation of 
erythropoiesis, the replication-deficient recombinant 
adenovirus AdMLP.EPO was constructed by deleting the 
majority of E1 from adenovirus type 5, and replacing E1 
with an expression cassette containing the adenovirus 
type 5 major late promoter (MLP) and the human EPO 
gene, including the 3’ cis-acting hypoxia response 
element. In vitro studies showed that infection of the 
human hepatocyte cell line Hep3B with AdMLP.EPO 
resulted in a 15-fold increase in EPO production in 24 h 
that was enhanced to 116-fold in the presence of a 
hypoxic stimulus. One-time in vivo administration of 
AdMLP.EPO (7 x 109 plaque-forming units/kg) to the 
peritoneum of cotton rats caused a marked increase in 
red blood cell production, with a 2.6-fold increase in bone 
marrow erythroid precursors by day 4, and sevenfold 
increase in reticulocyte count by day 7. The hematocrit 
increased gradually, with a maximum of 64 ± 4% at day 
14 (compared with an untreated baseline of 46 ± 2%), 
and a level of 55 ± 1% at day 24. Furthermore, one-time 
subcutaneous administration of AdMLP.EPO caused an 
increase in hematocrit that peaked at 14 days (57 ± 2%) 
and was still elevated at day 42. Hematocrit level in 
animals receiving subcutaneous administration of 
AdMLP. EPO sustained a long-term increase compared 
with animals receiving intraperitoneal administration. 
(Setaguchi et al., 1994). However considering the comp-
lexity and sensitivity of the physiological oxygen depen-
dent control of erythropoietin production in kidneys, it will 
be extremely difficult to achieve a similar regulation thro-
ugh autoregulated gene therapy (Rinsch et al., 997). 
Alternatively, systems of ligand dependent transgene 
regulation could be used, which involve specific activation 
of a transgene through different drugs. (Ye et al., 1999). 
The most important of the currently developed drug 
systems are those driven by tetracycline, a synthetic 
antiprogestin or chemical dimerizers such as rapamycin. 
With all three systems, iterative regulation of erythropoi-
etin secretion and haematocrit has been demonstrated in 
experimental animals depending on the systemic 
application of the respective ligand (Abbruzzese et al., 
2000). In the context of these observations, gene therapy 
with a single administration of an adenovirus vector 
containing the human EPO gene may provide a means of 
significantly augmenting the circulating red blood cell 
mass over the 1- to 3-week period necessary for many 
clinical applications (Eckardt et al., 2001).  
 
 
Potential of RHUEPO therapy 
 
There are currently four different RHUEPOs: ,β, δ and 
ω. However, only EPO- and EPO-β, are commercially 
available in the UK. Although these RHUEPOs act on the 
same erythropoietin receptor, there are some variations 
on the degree of glycosylation which lead to the 
differences in the pharmacokinetics and pharmacodyna-
mics among the RHUEPOs (Macdougall, 2001). It requi-
res a less frequent dosing schedule and produces a 
similar clinical outcome and safety profile as RHUEPOs 





nancy (Locatelli et al., 2001; Glaspy et al., 2001). Another 
strategy to enhance the biological activity of RHUEPO is 
to provide a “protective vehicle” so as to decrease the 
rate of elimination, thus prolonging the half-life of 
RHUEPO (Smith et al., 2001).  
The mechanism of action of erythropoietin is essential 
for the proliferation, differentiation and maturation of 
RBCs in bone marrow. Moreover, erythropoietin is critical 
for the survival of RBC progenitors in bone marrow and 
may also have immunomodulatory activity (Silva et al., 
1996). Erythropoietin functions by binding to the erythro-
poietin receptor, a member of the superfamily of cytokine 
receptors (Huraib et al., 1997). The number of erythropoi-
etin receptors varies during RBC differentiation. The 
number of erythropoietin to its receptor results in homodi-
merisation of the receptor followed by activation of 
several signal transduction pathways: JAK 2/STAT5 sys-
tem, G-protein (RAS), calcium channel and kinases (Tilb-
rook et al., 1999). RHUEPO can also be administrated to 
marrow donors. Engraftment was also obtained in all 
patients who received the marrow from the donors trea-
ted with rhEPO (Akiyama et al., 2005). 
Clinical studies have demonstrated that the subcutan-
eous route offers a few advantages over intravenous 
administration for instance; subcutaneous administration 
is more convenient as it does not require any venous 
access (Macdougall, 1998).  A large dose of RHUEPO 
may be required to maintain the same haemoglobin level 
if RHUEPO has to be applied intraperitoneally (Johnson 
et al., 1999). It remains uncertain whether similar mea-
sure will be applied to the other recombinant erythropoi-
etins (Ng’ et al., 2003). 
The frequency of administration by both intravenous 
and subcutaneous RHUEPO can be given from once 
daily to thrice, twice and once weekly in renal patients, 
depending on the clinical status of the patients. Recombi-
nant human erythropoietin is very much used as a vital 
and novel treatment for several anaemic related malfunc-
tions and disorders.  
 
 
Increased scope of recombinant human erythropoi-
etin therapy  
 
The increased scope of RHUEPO therapy impairs the 
factors such as renal dysfunction, hyperviscosity, inflame-
mation, infection, neoplasia, cancer chemotherapy, bone 
marrow transplantation, surgery, prematurity, pregnancy 
(Jerry and Spivak, 2002). Several findings suggest that 
treatment with EPO could be beneficial in anaemic 
patients with CHF, CRF and CNS.  These benefits effects 
on exercise and quality of life are seen whether the 
anaemia is true or dilutional in nature (Silverberg et al., 
2000; Silverberg et al., 2001). 
The novel treatment approaches are irrespective of 
how different potential future indications for RHUEPO will 
be, they will altogether increase the total need of the 
hormone, in particular, since several indications may req- 




uire doses much higher than those currently used in the 
dialysis population. The future of EPO will therefore, very 
much depend on its price. Expiration of current patents is 
foreseeable and will probably have a significant impact. 
Other developments are underway, which are likely to 
increase the number of providers, may result in 
alternative and less expensive methods of administration 
or will even lead to new therapeutic agents capable of 






Based on the effect of recombinant human erythropoietin 
on its receptor, investigations have been focused on 
searching for alternatives to enhance and stimulate ery-
thropoiesis. In the future, it is likely to envisage new 
development which optimizes and maximises erythropoi-
esis, thus shifting the paradigm of anaemia management. 
However, it will be necessary to define precisely the 
cost/benefit relationship for different indications as well as 
the optimal ways to use EPO and related therapies. The 
RHUEPO has become a challenge for surgeons, anes-
thesiologists, and transfusion as well as in combining the 
use of his product of biotechnology with other conser-
vation strategies. Given the enormous interest in this 
therapeutic approach, it seems to be promising in the 
future. Finally, the randomized clinical trails have to 
prove, if and at which speed, the theoretical advantages 
will be translated into clinical practice promoting strong 
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